dideoxy dye-terminator sequencing method (Virco Pharmaceuticals)
90
Structured Review
Virco Pharmaceuticals
dideoxy dye-terminator sequencing method
Dideoxy Dye Terminator Sequencing Method, supplied by Virco Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dideoxy+dye+terminator/dideoxy+dye+terminator+sequencing+method/pm19563238-44-9-18
Average 90 stars, based on 1 article reviews
Dideoxy Dye Terminator Sequencing Method, supplied by Virco Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/dideoxy+dye+terminator/dideoxy+dye+terminator+sequencing+method/pm19563238-44-9-18
Average 90 stars, based on 1 article reviews
dideoxy dye-terminator sequencing method - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Sequencing:Article Title: Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263). Article Snippet: COL40263 was a pilot 48-week, open-label, multicenter study evaluating the efficacy and safety of once-daily coformulated abacavir=lamivudine=zidovudine plus tenofovir in ART-naive, HIV-infected subjects.. We examined the patterns of resistance that were selected on-therapy through 48 weeks in subjects with virologic nonresponse (VF).. A total of 123 antiretroviral-naive HIV-1-infected subjects with plasma HIV-1 RNA 30,000 copies=ml were enrolled. Clinical Proteomics:Article Title: Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263). Article Snippet: COL40263 was a pilot 48-week, open-label, multicenter study evaluating the efficacy and safety of once-daily coformulated abacavir=lamivudine=zidovudine plus tenofovir in ART-naive, HIV-infected subjects.. We examined the patterns of resistance that were selected on-therapy through 48 weeks in subjects with virologic nonresponse (VF).. A total of 123 antiretroviral-naive HIV-1-infected subjects with plasma HIV-1 RNA 30,000 copies=ml were enrolled. Virus:Article Title: Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263). Article Snippet: COL40263 was a pilot 48-week, open-label, multicenter study evaluating the efficacy and safety of once-daily coformulated abacavir=lamivudine=zidovudine plus tenofovir in ART-naive, HIV-infected subjects.. We examined the patterns of resistance that were selected on-therapy through 48 weeks in subjects with virologic nonresponse (VF).. A total of 123 antiretroviral-naive HIV-1-infected subjects with plasma HIV-1 RNA 30,000 copies=ml were enrolled. |